Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026. Open the filing →
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
FAQ
- What is Monopar Therapeutics's EBIT?
- Monopar Therapeutics (MNPR) reported EBIT of -$5.23M in Q1 2026.
- How has Monopar Therapeutics's EBIT changed year-over-year?
- Monopar Therapeutics's EBIT decreased by 62.2% year-over-year, from -$3.22M to -$5.23M.
- What is the long-term trend for Monopar Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Monopar Therapeutics's EBIT has grown at a 16.3% compound annual growth rate (CAGR), from -$9.13M to -$16.7M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Monopar Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude